Parkinson's disease Nervous System Diseases
Conditions
Interventions
Healthy volunteers will be recruited and screening for blood, hepatic and renal functions will be performed to fulfill the inclusion criteria in this study.
Genotyping will be carried out for variant
Sponsors
University of Health Sciences Lahore
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Healthy volunteers of both sexes 2. Age between 18 to 30 years 3. Body Mass Index <30 (BMI=weight/height2) 4. Smoking will be defined as present if a participant reports to be smoking at the time of survey either daily or occasionally 5. Non-smoker is a person who does not smoke at all or at the time of survey
Exclusion criteria
Exclusion criteria: 1. Volunteers with unstable medical condition or deranged CBC, LFT & RFT 2. Volunteers with history of drug allergies 3. Volunteers who have received any medication which is substrate for CYP1A2 4. Volunteers who have donated blood within 2 months 5. Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose of rasagiline required to ensure effective plasma concentrations to achieve clinical response in participants with CYP1A2 A/A, A/C & C/C variant and smokers measured using pharmacokinetic variables (Cmax, Tmax, AUC, t1/2,Vd & Cl), at (0, 0.25, 0.30, 1,2,4,6, 8, 10 & 14 & 18hrs) | — |
Countries
Pakistan
Contacts
Public ContactRabiea Munir
Outcome results
None listed